## AGENDA

**Pharmacy and Therapeutics Committee**  
July 10, 2017  12:00pm -5:00 pm  
Gold Room, 3rd Floor  
701 E. Jefferson  Phoenix, AZ  85034

**Teleconference:** 1-877-820-7831  **Passcode:** 960711

| Noon | **Welcome and Introductions:** Sara Salek, MD, Chief Medical Officer, AHCCCS  
- April 13, 2017 P&T Minutes Review and Vote  
- Call for P&T Members for 2018 to 2020 |

### Agenda Topics

| 12:15 | **Supplemental Rebate Class Review:**  
1. Oral Atypical (Second Generation) Antipsychotics  
   a. Clinical review: Rick Pope: Provider Synergies  
   b. Pharma Testimony:  
      i. Rexulti: Kristin Pareja, Otsuka  
   c. Public Testimony:  
      i. Kurt von Behrmann, N.A.M.I. Family Support  
2. Long-Acting Injectable Antipsychotics  
   a. Clinical review: Rick Pope: Provider Synergies  
   b. Pharma Testimony:  
      i. Abilify Maintena: Kristin Pareja, Otsuka  
      ii. Aristada: Kenneth Berry, Alkermes  
      iii. Invega Sustenna: Steve Zona, Janssen Scientific Affairs  
      iv. Trinza: Steve Zona, Janssen Scientific Affairs  
   c. Public Testimony:  
      i. Mathew Avila, Community Health Associates  
      ii. Carol Olson MD, Maricopa Integrated Health System  
      iii. Thomas Gazda, MD  
      iv. Charles Goldstein, MD  
      v. Kristina Sabetta, Mental Health America of Arizona  
3. Stimulants & Related Agents  
   a. Clinical review: Rick Pope: Provider Synergies  
   b. Pharma Testimony:  
      i. Adzenys XR-ODT: George Kehner, Neos Therapeutics  
      ii. Aptensio XR: Christina Heiner, Rhodes Pharmaceuticals  
      iii. Dyanavel XR: Zulma Schlossberg, Tris Pharma  
      iv. Quillivant XR: Steve Fuchs, Pfizer  
      v. Quillichew: Steve Fuchs, Pfizer  
   c. Public Testimony: None  
4. Pancreatic Enzymes  
   a. Clinical review: Rick Pope: Provider Synergies  
   b. Pharma Testimony:  
   c. Public Testimony: None  
5. Anticoagulants  
   a. Clinical review: Rick Pope: Provider Synergies |
b. Pharma Testimony:
   i. Eliquis: Jon Glover, Pfizer
   ii. Xarelto: Steve Zona, Janssen Scientific Affairs

c. Public Testimony: None

Non-Supplemental Rebate Class Review:

1. Hemophilia Factor
   a. Clinical review: Rick Pope: Provider Synergies
   b. Pharma Testimony:
      i. Alprolix: Alex Bitting, Bioverativ
      ii. Eloctate: Alex Bitting, Bioverativ
      iii. Kogenate FS: Trina Ballard, Bayer
      iv. Kovaltry rFVIII: Trina Ballard, Bayer

C. Public Testimony:
   i. Danielle Nance, Arizona Bleeding Disorders Health and Wellness Center
   ii. Andrew Blacklidge, Arizona Hemophilia Association
   iii. Esteban Gomez, Phoenix Children’s Hospital Hemophilia Center
   iv. Josue Terazon
   v. Tyler Lipinski
   vi. David Cabrera
   vii. Tony Hernandez
   viii. Marco Bojorges
   ix. Brent Davila

Executive Session

3:15 Supplemental Rebate Class Discussions:
   • Hypoglycemics, Insulin & Related Agents – postponed until the July meeting to review additional data.
   • Oral Atypical (Second Generation) Antipsychotics
   • Long-Acting Injectable Antipsychotics
   • Stimulants & Related Agents
   • Pancreatic Enzymes
   • Anticoagulants

Non-Supplemental Rebate Class Discussion:
   • Hemophilia Factor

Break

Public Therapeutic Class Votes

4:00 AHCCCS Drug Lists Alignment for Behavioral Health Drugs & Vote – Michelle Cavner, Pharmacy Director, MMIC

4:20 Biosimilar Update:
   • Inflectra (infliximab-dyyb)
   • b. Renflexis (Infliximab-abda)

4:25 New Drug Reviews: Non-Supplemental Rebate Class: Suzi Berman, AHCCCS
   • Austedo (Deutertrabenazine)
   • Dupixent (Dupiluma)
   • Rhofade (Oxymetazoline HCL 1% Cream)
   • Symproic (Naldemedine)
   • Xadago (Safinamide)
   • Ingrezza (Valbenazine)
   • Emflaza (Deflazacort)
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>5:00</td>
<td>Meeting Adjourned</td>
</tr>
</tbody>
</table>

**2017 Meeting Dates:** Thursday, October 12, 2017